Responses
Clinical/translational cancer immunotherapy
Original research
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
Compose a Response to This Article
Other responses
No responses have been published for this article.